Acta Med. 2011, 54: 177-179
https://doi.org/10.14712/18059694.2016.46
Sorafenib, Risk of Bleeding and Spontaneous Rupture of Hepatocellular Carcinoma. A Clinical Case
References
1. Eur Rev Med Pharmacol Sci 2010; 14: 352–5.
G, Craxì A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma.
2. Korean J Hepatol 2009; 15: 148–58.
< YI, Ki HS, Kim MH, et al. [Analysis of the clinical characteristics and prognostic factors of ruptured hepatocellular carcinoma]. https://doi.org/10.3350/kjhep.2009.15.2.148>
3. Eur J Surg Oncol; 2000; 26: 770–2.
< V, Muratore A, Bouzari H, et al. Spontaneous rupture of hepatocellular carcinoma: surgical resection and long term survival. https://doi.org/10.1053/ejso.2000.1001>
4. Am J Gastroenterol 1991; 86: 67–71.
M, Sudo T, Kuyama T. Spontaneous rupture of hepatocellular carcinoma: a review of 172 Japanese cases.
5. Br J Surg 2002; 89: 1125–9.
< CN, Lee WC, Jeng LB, Chen MF, Yu MC. Spontaneous tumour rupture and prognosis in patients with hepatocellular carcinoma. https://doi.org/10.1046/j.1365-2168.2002.02188.x>
6. ANZ J Surg 2006; 76: 448–52.
< FL, Tan YM, Chung AY, Cheow PC, Chow PK, Ooi LL. Factors affecting early mortality in spontaneous rupture of hepatocellular carcinoma. https://doi.org/10.1111/j.1445-2197.2006.03750.x>
7. BMC Gastroenterol 2009; 9: 29.
< H, Saito S, Yoneda M, et al. Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study. https://doi.org/10.1186/1471-230X-9-29>
<PubMed>
8. Arch Surg 2006; 141: 191–8.
< EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. https://doi.org/10.1001/archsurg.141.2.191>
9. Br J Radiol 2001; 74: 142–6.
< BG, Park SH, Byun JY, Jung SE, Choi KH, Han JY. The findings of ruptured hepatocellular carcinoma on helical CT. https://doi.org/10.1259/bjr.74.878.740142>
10. Eur J Surg 1995; 161: 881–6.
M, Cavallari A, Bellusci R, De Raffaele E, Nardo B, Gozzetti G. Ruptured hepatocellular carcinoma: an important cause of spontaneous haemoperitoneum in Italy.
11. Am J Surg 2009; 197: 164–7.
< N, Madanur M, Priest O, et al. Spontaneous rupture of hepatocellular carcinoma: a Western experience. https://doi.org/10.1016/j.amjsurg.2007.10.016>
12. World J Gastroenterol 2010; 16: 1221–5.
< N, Caratozzolo E, Bonariol L, et al. Management of ruptured hepatocellular carcinoma: Implications for therapy. https://doi.org/10.3748/wjg.v16.i10.1221>
<PubMed>
13. N Engl J Med 2008; 359: 378–90.
< JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. https://doi.org/10.1056/NEJMoa0708857>
14. Lancet Oncol 2009; 10: 967–74.
< Y, Schutz FAB, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. https://doi.org/10.1016/S1470-2045(09)70222-0>
15. Br J Cancer 2007; 96: 1788–95.
< T, McDonald DM. Mechanism of adverse effects of anti-VEGF therapy for cancer. https://doi.org/10.1038/sj.bjc.6603813>
<PubMed>